Commission file number: 0-18892
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For May/June 2005
MAYNE GROUP LIMITED
(Translation of Registrant’s Name into English)
Mayne Group House
21/390 St Kilda Road
Melbourne, Victoria 3004
Australia
(Address of Principal Executive Offices)
(Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.)
Form 20-F X Form 40-F
(Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.)
Yes No X .
(If “Yes is marked indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- .)
Media Releases / ASX Announcements
Exhibit 1 – Share buy-back
Exhibit 2 - Mayne announces Board appointments
EXHIBIT 1
12 May 2005
Company Announcements Office
Australian Stock Exchange
Level 4
20 Bridge Street
Sydney NSW 2000
Dear Sir
Re: Share buy-back
Mayne Group Limited announced on 4 May 2005 that it is undertaking a strategic review to assess the merits of a demerger involving separate listings of its pharmaceutical and healthcare businesses and, if a demerger is undertaken, the optimal configuration of the listed entities. In light of this review, based on legal advice the company has decided to suspend purchases under its on-market share buy-back announced on 8 March 2005 until either the strategic review is completed or notice is given that the buy-back is to be resumed.
For the avoidance of doubt, the Appendix 3F Final Share Buy-Back Notice filed on 23 March 2005 related to the on-market buy-back programme announced on 1 March 2004 (as amended on 22 March 2004) and did not affect the on-market share buy-back announced on 8 March 2005.
Yours faithfully
| Mayne Group Limited |
/s/Timothy A. Paine |
| Timothy A. Paine |
| Company Secretary |
EXHIBIT 2
Media and ASX Release
8 June 2005
Mayne announces Board appointments
Mayne Group Limited (ASX:MAY) today announced the appointment of two new non-executive Directors to the Mayne Board, Mr James (Jim) Hall and Mr Paul McClintock.
Mr Hall has more than 35 years in senior financial management roles. Most recently Mr Hall was Executive Director of Finance at Orica Limited, a role he held since January 2002. In his time at Orica, Mr Hall was a key member of the senior management team, during a period when the financial performance of Orica’s established businesses improved significantly. Retiring from Orica in April 2005, Mr Hall was briefly a Director of Affinity Health as it prepared for an ASX listing. He is currently a Director of Qenos Holdings Pty Ltd and will join the Board of Alesco Corporation Limited on 1 July 2005.
Prior to joining Orica, Mr Hall was Vice President, Group Accounting and Controller at BHP Billiton. In his 32 years at BHP, Mr Hall held a range of senior financial management roles. Mr Hall had significant experience in both merger and demerger activities during his time at BHP.
Mr McClintock is a qualified lawyer, with an extensive career in corporate advisory and government. Since 1985 he has been a principal of the private investment banking firm, McClintock Associates, apart from 2000-2003 when he served as Secretary to Cabinet and Head of the Cabinet Policy Unit, reporting directly to the Prime Minister.
Mr McClintock has a strong background in health, serving as Chairman of Affinity Health from January 2004 to April 2005. He is currently a Director of ANZAC Medical Research Centre and a Commissioner of the Health Insurance Commission. Other directorships currently held by Mr McClintock are Chairman of Thales Australia Group, Director of Perpetual Trustees Australia Limited and Director of Macquarie Infrastructure Group.
Mayne’s Chairman, Mr Peter Willcox, said he was delighted to welcome Mr Hall and Mr McClintock to the Board.
“The demerger review process is progressing well and the Board’s appointment of two additional non-executive Directors is an important development in the process.
“Both Directors will be invaluable to Mayne during the demerger review and in the next phase of development of the company. In particular, both Mr Hall and Mr McClintock have experience in the rigorous process of preparing a company for listing through their recent directorships at Affinity Health,” he said.
Mr Hall’s and Mr McClintock’s appointments are effective today, 8 June 2005, and they will both stand for election at the 2005 Annual General Meeting. Should the demerger proceed, it is anticipated that Mr Hall and Mr McClintock will each serve as a Director of one of the demerged entities.
EXHIBIT 2
About Mayne Group Limited
Mayne Group Limited is listed on the Australian Stock Exchange and has businesses in international specialty pharmaceuticals (the manufacture of injectable and oral pharmaceuticals for distribution to more than 50 countries), diagnostic services (pathology, diagnostic imaging and medical centres), pharmacy, and health-related consumer products.
oooo0000oooo
| Media enquiries | Investor enquiries | |
| Jason Thomas | Caroline Ingham | |
| Communications Manager | Investor Relations Manager | |
| Ph: +61 3 9868 0706 | Ph: +61 3 9868 0894 | |
| Mb: +61 421 341 709 | Mb: +61 419 526 355 | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| MAYNE GROUP LIMITED | ||
| By: | /s/ Timothy Paine | |
| Name: | Timothy Paine | |
| Title: | Company Secretary | |
Date: 8 June 2005
